Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NK Cell Infusion · 1 trial · 5 indications
Maximum tolerated dose (MTD) is the highest dose with 10 patients treated and 5 or fewer patients with DLT.
| Arm | Type | Description |
|---|---|---|
| Immunotherapy with NK Cell, Rituximab + GM-CSF | EXPERIMENTAL | Immunotherapy in Non-myeloablative Allogeneic Stem Cell Transplantation GM-CSF = Granulocyte-Macrophage Colony-Stimulating Factor |
| Name | Type | Description |
|---|---|---|
| GM-CSF | DRUG | 250 micrograms subcutaneously 3 times a week for 4 weeks starting a day before the administration of Rituximab. |
| Rituximab | DRUG | 375 mg/m\^2 by vein followed by 1000 mg/m\^2 weekly for 3 weeks for a total of 4 doses. |
| NK Cell Infusion | BIOLOGICAL | NK cells will be infused one week after the fourth dose of Rituximab and GM-CSF. |
Inclusion Criteria: 1. Patients with previous diagnosis of CD20+ B-cell CLL and non-Hodgkin's lymphoma who have failed standard conventional chemotherapy, and who had persistent disease at 3 months, or progressive disease after non-myeloablative allogeneic transplantation. 2. Donor willingness to d...
Top 20 of 68 competitors